Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 +6.3%	$1.22	$0.86 ▼ $3.78	$248.51M	0.35	5.56 million shs	7.30 million shs
BTAI BioXcel Therapeutics	$4.98 -4.8%	$2.69	$1.17 ▼ $13.36	$31.67M	0.05	25.23 million shs	3.91 million shs
BYND Beyond Meat	$2.45 +2.5%	$3.25	$2.22 ▼ $7.60	$183.18M	2.22	2.33 million shs	2.09 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+6.25%	+8.18%	-28.31%	+12.26%	-56.57%
BTAI BioXcel Therapeutics	-4.78%	-9.12%	+175.14%	+258.27%	-54.26%
BYND Beyond Meat	+2.51%	-5.04%	-42.76%	-14.04%	-61.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.8367 of 5 stars	3.4	3.0	0.0	2.2	2.5	0.6
BTAI BioXcel Therapeutics	4.5818 of 5 stars	3.4	5.0	4.5	3.0	1.7	0.6
BYND Beyond Meat	2.9511 of 5 stars	2.6	0.0	3.4	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	609.62% Upside
BTAI BioXcel Therapeutics	2.80	Moderate Buy	$39.75	698.19% Upside
BYND Beyond Meat	1.25	Strong Sell	$3.67	49.66% Upside

Current Analyst Ratings Breakdown

Latest BYND, ALLO, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	BYND Beyond Meat	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight ➝ Underweight
8/15/2025	BTAI BioXcel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00
8/14/2025	BYND Beyond Meat	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$5.00 ➝ $4.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	$1.55 per share	N/A
BTAI BioXcel Therapeutics	$868K	34.75	N/A	N/A	($7.40) per share	-0.67
BYND Beyond Meat	$301.35M	0.62	N/A	N/A	($8.83) per share	-0.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
BTAI BioXcel Therapeutics	-$59.60M	-$12.64	N/A	N/A	N/A	-5,869.82%	N/A	-134.45%	N/A
BYND Beyond Meat	-$160.28M	-$2.18	N/A	N/A	N/A	-52.27%	N/A	-22.97%	11/5/2025 (Estimated)

Latest BYND, ALLO, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/12/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	-$2.45	-$0.15	-$2.45	$0.21 million	$0.12 million
8/6/2025	Q2 2025	BYND Beyond Meat	-$0.37	-$0.43	-$0.06	-$0.43	$85.71 million	$74.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
BYND Beyond Meat	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
BTAI BioXcel Therapeutics	N/A	0.76	0.74
BYND Beyond Meat	N/A	3.29	2.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
BTAI BioXcel Therapeutics	30.68%
BYND Beyond Meat	52.48%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
BTAI BioXcel Therapeutics	21.20%
BYND Beyond Meat	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
BYND Beyond Meat	880	76.65 million	70.90 million	Optionable

BYND, ALLO, and BTAI Headlines

Recent News About These Companies

Beyond Meat snaps six straight sessions of losses

August 22 at 6:17 PM | msn.com

Mizuho Securities Keeps Their Sell Rating on Beyond Meat (BYND)

August 22 at 8:16 AM | theglobeandmail.com

Beyond Meat (NASDAQ:BYND) Given Underweight Rating at JPMorgan Chase & Co.

August 22 at 8:05 AM | marketbeat.com

JPMorgan Chase & Co. Initiates Coverage on Beyond Meat (NASDAQ:BYND)

August 21 at 4:19 AM | americanbankingnews.com

Beyond Meat assumed with an Underweight at JPMorgan

August 21 at 2:15 AM | msn.com

JP Morgan updates food sector coverage; favors McCormick, Albertsons, and Hormel

August 20 at 8:14 PM | msn.com

Beyond Meat: Sales Challenges Deepen In Q2 2025

August 17, 2025 | seekingalpha.com

Beyond Meat stock falls amid bankruptcy speculation

August 16, 2025 | investing.com

Beyond Meat Stock (BYND) Gets Binned Despite Rubbishing Bankruptcy Fears

August 16, 2025 | msn.com

BMO Capital Markets Lowers Beyond Meat (NASDAQ:BYND) Price Target to $4.00

August 16, 2025 | marketbeat.com

Beyond Meat pushes back on The Street contention company ‘headed to’ bankruptcy

August 16, 2025 | msn.com

Why Beyond Meat (BYND) Stock Is Trading Lower Today

August 16, 2025 | finance.yahoo.com

Beyond Meat, facing financial pressure amid falling sales, denies bankruptcy rumors

August 15, 2025 | proactiveinvestors.com

5 Insightful Analyst Questions From Beyond Meat’s Q2 Earnings Call

August 14, 2025 | finance.yahoo.com

Is plant-based protein a fad on its way out?

August 12, 2025 | wattagnet.comW

Beyond Meat (BYND) Stock Trades Up, Here Is Why

August 12, 2025 | uk.finance.yahoo.com

BYND Q2 Deep Dive: Category Headwinds Prompt Operational Reset and Brand Refocus

August 12, 2025 | finance.yahoo.com

Beyond Meat: Bankruptcy Chances Surge After Disaster Q2 Report

August 9, 2025 | seekingalpha.com

Beyond Meat Delays Q2 2025 Financial Report

August 8, 2025 | tipranks.com

Retail investors account for 50% of Beyond Meat, Inc.'s (NASDAQ:BYND) ownership, while institutions account for 45%

August 8, 2025 | uk.finance.yahoo.com

Beyond Meat Announces Workforce Reduction to Cut Costs

August 8, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYND, ALLO, and BTAI Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.19 +0.07 (+6.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.03 (+2.52%)

As of 08/22/2025 07:49 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

BioXcel Therapeutics NASDAQ:BTAI

$4.98 -0.25 (-4.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.00 +0.02 (+0.42%)

As of 08/22/2025 07:59 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Beyond Meat NASDAQ:BYND

$2.45 +0.06 (+2.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.52 +0.07 (+3.06%)

As of 08/22/2025 07:59 PM Eastern

Beyond Meat, Inc., a plant-based meat company, develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club stores, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was incorporated in 2008 and is headquartered in El Segundo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time